English
简体中文
Total: £ 56.28
Published Date: 2026-01-13 | Pages: 111 | Tables: 115 | Pharma & Healthcare
The global Urokinase Injection market was valued at US$ 313 million in 2025 and is anticipated to reach US$ 476 million by 2032, at a CAGR of 6.3% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Urokinase Injection competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The urokinase injection market refers to the clinical and commercial use of injectable urokinase (urokinase for injection)—a “clot-dissolving” medicine used in hospitals to break down unwanted blood clots. Urokinase works by acting on the body’s natural fibrinolytic system: it converts plasminogen into plasmin, and plasmin then breaks down fibrin clots (and also affects fibrinogen and some other plasma proteins). Because urokinase is given by injection/infusion and can cause serious bleeding, its use is typically limited to settings where doctors can monitor patients closely (emergency departments, intensive care units, catheter labs, interventional radiology suites, vascular surgery wards, and specialized stroke or thrombosis centers).
In practical terms, the market is defined by where and how urokinase injection is used. In some jurisdictions, product labeling and clinical practice include use for pulmonary embolism (blood clots in the lungs), for catheter-directed thrombolysis in peripheral arteries or graft occlusions, and for restoring patency of intravenous catheters blocked by clotted blood or fibrin. This “hospital procedure drug” positioning is important: urokinase injection is not a long-term prevention drug like oral anticoagulants; it is more often a time-sensitive rescue therapy or a procedure-support drug used when a clot is already causing acute risk or blocking a device.
A key part of the market definition is also the dosage form and supply chain. Urokinase products are commonly supplied as a sterile lyophilized (freeze-dried) powder that must be reconstituted before use. These factors make urokinase different from many small-molecule injectables: producers must manage complex upstream cell culture, purification, sterile fill-finish, and strict quality control, and buyers care about lot consistency and supply reliability.
In 2025, global Urokinase Injection production reached approximately 15.6 million Units, with an average global market price of around US$ 20.1 per Units. The global single-line production capacity ranges from 350 to 500 K Units per year. The industry's gross profit margin is approximately 25%-35%.
On market trends, one broad trend is that thrombolysis is being shaped by newer thrombolytic agents, improved imaging, and more interventional procedures. In acute ischemic stroke, for example, many global guidelines focus on intravenous alteplase (and increasingly tenecteplase as an alternative in some systems) within defined time windows, and mechanical thrombectomy has expanded in selected patients. This matters for urokinase because it changes where urokinase is positioned: in many countries, urokinase is not the primary stroke thrombolytic, while in others it is used as a lower-cost or locally available option. A recent review notes that urokinase has been approved and used in China for years and that Chinese guidance has recommended intravenous urokinase within certain time windows for acute ischemic stroke, with commonly cited dosing ranges (for example 1,000,000–1,500,000 IU in that context). So, the stroke segment shows a “two-track” trend: in some regions, practice is consolidating around rt-PA/tenecteplase and thrombectomy pathways, while in other regions, urokinase remains relevant due to access, cost, and local evidence bases.
A second trend is the growth of catheter use in modern medicine, which tends to expand the catheter-clearance opportunity for thrombolytics, including urokinase. Central venous catheters and other long-term lines are widely used for chemotherapy, parenteral nutrition, long courses of IV antibiotics, and repeated blood draws. The clinical literature describes catheter occlusion as a frequent complication and reviews thrombolytic options for restoring patency. In that review, several thrombolytic agents (including recombinant urokinase) are discussed with reported catheter clearance rates and time-to-clearance outcomes, and the paper also notes that thrombolytic prophylaxis in some studies reduced catheter occlusion incidence. Even if individual studies vary, the practical market implication is straightforward: as the number of patients dependent on long-term catheters rises (cancer care, home infusion, complex pediatrics, dialysis pathways), hospitals place higher value on reliable, fast methods to reopen lines and avoid line replacement procedures.
A third trend is a procedural shift toward targeted therapy in vascular care. For some vascular occlusions, clinicians may prefer catheter-directed approaches that localize treatment at the clot, often aiming to improve efficacy while limiting systemic exposure and bleeding risk. Urokinase has a history of use in catheter-directed settings (for example, peripheral arterial and graft thromboembolic occlusion described in product monographs). At the same time, competition is intense: other thrombolytics (alteplase, tenecteplase, reteplase in certain contexts) and mechanical strategies (aspiration, thrombectomy devices, angioplasty/stenting) all influence whether a hospital uses urokinase, which dose, and for which patients. This competitive pressure pushes the urokinase market toward niches where it has clear operational or economic advantages (availability, protocol familiarity, cost, or suitability for a specific catheter-clearance workflow).
This report delivers a comprehensive overview of the global Urokinase Injection market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Urokinase Injection. The Urokinase Injection market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Urokinase Injection market comprehensively. Regional market sizes by Type, by Application, by Clinical Use, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Urokinase Injection manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Syner-Med
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems
LIVZON
Wuhan Humanwell Pharma
Tianjin Biochem Pharma
Segment by Type
10000-100000IU
100000-1000000IU
Others
Segment by Clinical Use
Pulmonary Embolism Thrombolysis
Deep Vein Thrombosis
Peripheral Arterial Occlusion Thrombolysis
Catheter / Cannula Occlusion Clearance
Others
Segment by Administration Approach
Systemic Infusion
Catheter-directed Thrombolysis (CDT)
Intracatheter Dwell / Lock Technique
Segment by Purity
Standard Clinical Grade
High-purity / Low-impurity Grade
Low Endotoxin / Low Bioburden Specifications
by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Clinical Use, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Urokinase Injection manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Urokinase Injection sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Urokinase Injection Market Overview
1.1 Product Definition
1.2 Urokinase Injection by Type
1.2.1 Global Urokinase Injection Market Value by Type: 2025 vs 2032
1.2.2 10000-100000IU
1.2.3 100000-1000000IU
1.2.4 Others
1.3 Urokinase Injection by Clinical Use
1.3.1 Global Urokinase Injection Market Value by Clinical Use: 2025 vs 2032
1.3.2 Pulmonary Embolism Thrombolysis
1.3.3 Deep Vein Thrombosis
1.3.4 Peripheral Arterial Occlusion Thrombolysis
1.3.5 Catheter / Cannula Occlusion Clearance
1.3.6 Others
1.4 Urokinase Injection by Administration Approach
1.4.1 Global Urokinase Injection Market Value by Administration Approach: 2025 vs 2032
1.4.2 Systemic Infusion
1.4.3 Catheter-directed Thrombolysis (CDT)
1.4.4 Intracatheter Dwell / Lock Technique
1.5 Urokinase Injection by Purity
1.5.1 Global Urokinase Injection Market Value by Purity: 2025 vs 2032
1.5.2 Standard Clinical Grade
1.5.3 High-purity / Low-impurity Grade
1.5.4 Low Endotoxin / Low Bioburden Specifications
1.6 Urokinase Injection by Application
1.6.1 Global Urokinase Injection Market Value by Application: 2025 vs 2032
1.6.2 Hospital
1.6.3 Clinic
1.6.4 Others
1.7 Global Urokinase Injection Market Size Estimates and Forecasts
1.7.1 Global Urokinase Injection Revenue 2021–2032
1.7.2 Global Urokinase Injection Sales 2021–2032
1.7.3 Global Urokinase Injection Market Average Price (2021–2032)
1.8 Assumptions and Limitations
2 Urokinase Injection Market Competition by Manufacturers
2.1 Global Urokinase Injection Sales Market Share by Manufacturers (2021–2026)
2.2 Global Urokinase Injection Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Urokinase Injection Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Urokinase Injection, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Urokinase Injection, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Urokinase Injection, Product Types and Applications
2.7 Global Key Manufacturers of Urokinase Injection, Date of Entry into the Industry
2.8 Global Urokinase Injection Market Competitive Situation and Trends
2.8.1 Global Urokinase Injection Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Urokinase Injection Players Market Share by Revenue
2.8.3 Global Urokinase Injection Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Urokinase Injection Market Scenario by Region
3.1 Global Urokinase Injection Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Urokinase Injection Sales by Region: 2021–2032
3.2.1 Global Urokinase Injection Sales by Region: 2021–2026
3.2.2 Global Urokinase Injection Sales by Region: 2027–2032
3.3 Global Urokinase Injection Revenue by Region: 2021–2032
3.3.1 Global Urokinase Injection Revenue by Region: 2021–2026
3.3.2 Global Urokinase Injection Revenue by Region: 2027–2032
3.4 North America Urokinase Injection Market Facts & Figures by Country
3.4.1 North America Urokinase Injection Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Urokinase Injection Sales by Country (2021–2032)
3.4.3 North America Urokinase Injection Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Urokinase Injection Market Facts & Figures by Country
3.5.1 Europe Urokinase Injection Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Urokinase Injection Sales by Country (2021–2032)
3.5.3 Europe Urokinase Injection Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Urokinase Injection Market Facts & Figures by Region
3.6.1 Asia Pacific Urokinase Injection Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Urokinase Injection Sales by Region (2021–2032)
3.6.3 Asia Pacific Urokinase Injection Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Urokinase Injection Market Facts & Figures by Country
3.7.1 Latin America Urokinase Injection Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Urokinase Injection Sales by Country (2021–2032)
3.7.3 Latin America Urokinase Injection Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Urokinase Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Urokinase Injection Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Urokinase Injection Sales by Country (2021–2032)
3.8.3 Middle East and Africa Urokinase Injection Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Urokinase Injection Sales by Type (2021–2032)
4.1.1 Global Urokinase Injection Sales by Type (2021–2026)
4.1.2 Global Urokinase Injection Sales by Type (2027–2032)
4.1.3 Global Urokinase Injection Sales Market Share by Type (2021–2032)
4.2 Global Urokinase Injection Revenue by Type (2021–2032)
4.2.1 Global Urokinase Injection Revenue by Type (2021–2026)
4.2.2 Global Urokinase Injection Revenue by Type (2027–2032)
4.2.3 Global Urokinase Injection Revenue Market Share by Type (2021–2032)
4.3 Global Urokinase Injection Price by Type (2021–2032)
5 Segment by Application
5.1 Global Urokinase Injection Sales by Application (2021–2032)
5.1.1 Global Urokinase Injection Sales by Application (2021–2026)
5.1.2 Global Urokinase Injection Sales by Application (2027–2032)
5.1.3 Global Urokinase Injection Sales Market Share by Application (2021–2032)
5.2 Global Urokinase Injection Revenue by Application (2021–2032)
5.2.1 Global Urokinase Injection Revenue by Application (2021–2026)
5.2.2 Global Urokinase Injection Revenue by Application (2027–2032)
5.2.3 Global Urokinase Injection Revenue Market Share by Application (2021–2032)
5.3 Global Urokinase Injection Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Syner-Med
6.1.1 Syner-Med Company Information
6.1.2 Syner-Med Description and Business Overview
6.1.3 Syner-Med Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Syner-Med Urokinase Injection Product Portfolio
6.1.5 Syner-Med Recent Developments/Updates
6.2 Wanhua Biochem
6.2.1 Wanhua Biochem Company Information
6.2.2 Wanhua Biochem Description and Business Overview
6.2.3 Wanhua Biochem Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Wanhua Biochem Urokinase Injection Product Portfolio
6.2.5 Wanhua Biochem Recent Developments/Updates
6.3 Jiangxi Haoran Bio-Pharma
6.3.1 Jiangxi Haoran Bio-Pharma Company Information
6.3.2 Jiangxi Haoran Bio-Pharma Description and Business Overview
6.3.3 Jiangxi Haoran Bio-Pharma Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Jiangxi Haoran Bio-Pharma Urokinase Injection Product Portfolio
6.3.5 Jiangxi Haoran Bio-Pharma Recent Developments/Updates
6.4 Jiangsu Aidea Pharmaceutical
6.4.1 Jiangsu Aidea Pharmaceutical Company Information
6.4.2 Jiangsu Aidea Pharmaceutical Description and Business Overview
6.4.3 Jiangsu Aidea Pharmaceutical Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Jiangsu Aidea Pharmaceutical Urokinase Injection Product Portfolio
6.4.5 Jiangsu Aidea Pharmaceutical Recent Developments/Updates
6.5 Techpool
6.5.1 Techpool Company Information
6.5.2 Techpool Description and Business Overview
6.5.3 Techpool Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Techpool Urokinase Injection Product Portfolio
6.5.5 Techpool Recent Developments/Updates
6.6 Microbic Biosystems
6.6.1 Microbic Biosystems Company Information
6.6.2 Microbic Biosystems Description and Business Overview
6.6.3 Microbic Biosystems Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Microbic Biosystems Urokinase Injection Product Portfolio
6.6.5 Microbic Biosystems Recent Developments/Updates
6.7 LIVZON
6.7.1 LIVZON Company Information
6.7.2 LIVZON Description and Business Overview
6.7.3 LIVZON Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 LIVZON Urokinase Injection Product Portfolio
6.7.5 LIVZON Recent Developments/Updates
6.8 Wuhan Humanwell Pharma
6.8.1 Wuhan Humanwell Pharma Company Information
6.8.2 Wuhan Humanwell Pharma Description and Business Overview
6.8.3 Wuhan Humanwell Pharma Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Wuhan Humanwell Pharma Urokinase Injection Product Portfolio
6.8.5 Wuhan Humanwell Pharma Recent Developments/Updates
6.9 Tianjin Biochem Pharma
6.9.1 Tianjin Biochem Pharma Company Information
6.9.2 Tianjin Biochem Pharma Description and Business Overview
6.9.3 Tianjin Biochem Pharma Urokinase Injection Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Tianjin Biochem Pharma Urokinase Injection Product Portfolio
6.9.5 Tianjin Biochem Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Urokinase Injection Industry Chain Analysis
7.2 Urokinase Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Urokinase Injection Production Mode & Process Analysis
7.4 Urokinase Injection Sales and Marketing
7.4.1 Urokinase Injection Sales Channels
7.4.2 Urokinase Injection Distributors
7.5 Urokinase Injection Customer Analysis
8 Urokinase Injection Market Dynamics
8.1 Urokinase Injection Industry Trends
8.2 Urokinase Injection Market Drivers
8.3 Urokinase Injection Market Challenges
8.4 Urokinase Injection Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Urokinase Injection Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Urokinase Injection Market Value by Clinical Use (US$ Million), 2025 vs 2032
Table 3. Global Urokinase Injection Market Value by Administration Approach (US$ Million), 2025 vs 2032
Table 4. Global Urokinase Injection Market Value by Purity (US$ Million), 2025 vs 2032
Table 5. Global Urokinase Injection Market Value by Application (US$ Million), 2025 vs 2032
Table 6. Global Urokinase Injection Market Competitive Situation by Manufacturers in 2025
Table 7. Global Urokinase Injection Sales (K Units) of Key Manufacturers (2021–2026)
Table 8. Global Urokinase Injection Sales Market Share by Manufacturers (2021–2026)
Table 9. Global Urokinase Injection Revenue (US$ Million) by Manufacturers (2021–2026)
Table 10. Global Urokinase Injection Revenue Share by Manufacturers (2021–2026)
Table 11. Global Market Urokinase Injection Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 12. Global Key Players of Urokinase Injection, Industry Ranking, 2023 vs 2024 vs 2025
Table 13. Global Key Manufacturers of Urokinase Injection, Manufacturing Sites and Headquarters
Table 14. Global Key Manufacturers of Urokinase Injection, Product Types and Applications
Table 15. Global Key Manufacturers of Urokinase Injection, Date of Entry into the Industry
Table 16. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Urokinase Injection Companies by Tier (Tier 1, Tier 2, Tier 3), based on Urokinase Injection Revenue, 2025
Table 18. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 19. Global Urokinase Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 20. Global Urokinase Injection Sales by Region (K Units), 2021–2026
Table 21. Global Urokinase Injection Sales Market Share by Region (2021–2026)
Table 22. Global Urokinase Injection Sales by Region (K Units), 2027–2032
Table 23. Global Urokinase Injection Sales Market Share by Region (2027–2032)
Table 24. Global Urokinase Injection Revenue by Region (US$ Million), 2021–2026
Table 25. Global Urokinase Injection Revenue Market Share by Region (2021–2026)
Table 26. Global Urokinase Injection Revenue by Region (US$ Million), 2027–2032
Table 27. Global Urokinase Injection Revenue Market Share by Region (2027–2032)
Table 28. North America Urokinase Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 29. North America Urokinase Injection Sales by Country (K Units), 2021–2026
Table 30. North America Urokinase Injection Sales by Country (K Units), 2027–2032
Table 31. North America Urokinase Injection Revenue by Country (US$ Million), 2021–2026
Table 32. North America Urokinase Injection Revenue by Country (US$ Million), 2027–2032
Table 33. Europe Urokinase Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Europe Urokinase Injection Sales by Country (K Units), 2021–2026
Table 35. Europe Urokinase Injection Sales by Country (K Units), 2027–2032
Table 36. Europe Urokinase Injection Revenue by Country (US$ Million), 2021–2026
Table 37. Europe Urokinase Injection Revenue by Country (US$ Million), 2027–2032
Table 38. Asia Pacific Urokinase Injection Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 39. Asia Pacific Urokinase Injection Sales by Region (K Units), 2021–2026
Table 40. Asia Pacific Urokinase Injection Sales by Region (K Units), 2027–2032
Table 41. Asia Pacific Urokinase Injection Revenue by Region (US$ Million), 2021–2026
Table 42. Asia Pacific Urokinase Injection Revenue by Region (US$ Million), 2027–2032
Table 43. Latin America Urokinase Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 44. Latin America Urokinase Injection Sales by Country (K Units), 2021–2026
Table 45. Latin America Urokinase Injection Sales by Country (K Units), 2027–2032
Table 46. Latin America Urokinase Injection Revenue by Country (US$ Million), 2021–2026
Table 47. Latin America Urokinase Injection Revenue by Country (US$ Million), 2027–2032
Table 48. Middle East and Africa Urokinase Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Middle East and Africa Urokinase Injection Sales by Country (K Units), 2021–2026
Table 50. Middle East and Africa Urokinase Injection Sales by Country (K Units), 2027–2032
Table 51. Middle East and Africa Urokinase Injection Revenue by Country (US$ Million), 2021–2026
Table 52. Middle East and Africa Urokinase Injection Revenue by Country (US$ Million), 2027–2032
Table 53. Global Urokinase Injection Sales (K Units) by Type (2021–2026)
Table 54. Global Urokinase Injection Sales (K Units) by Type (2027–2032)
Table 55. Global Urokinase Injection Sales Market Share by Type (2021–2026)
Table 56. Global Urokinase Injection Sales Market Share by Type (2027–2032)
Table 57. Global Urokinase Injection Revenue (US$ Million) by Type (2021–2026)
Table 58. Global Urokinase Injection Revenue (US$ Million) by Type (2027–2032)
Table 59. Global Urokinase Injection Revenue Market Share by Type (2021–2026)
Table 60. Global Urokinase Injection Revenue Market Share by Type (2027–2032)
Table 61. Global Urokinase Injection Price (US$/Unit) by Type (2021–2026)
Table 62. Global Urokinase Injection Price (US$/Unit) by Type (2027–2032)
Table 63. Global Urokinase Injection Sales (K Units) by Application (2021–2026)
Table 64. Global Urokinase Injection Sales (K Units) by Application (2027–2032)
Table 65. Global Urokinase Injection Sales Market Share by Application (2021–2026)
Table 66. Global Urokinase Injection Sales Market Share by Application (2027–2032)
Table 67. Global Urokinase Injection Revenue (US$ Million) by Application (2021–2026)
Table 68. Global Urokinase Injection Revenue (US$ Million) by Application (2027–2032)
Table 69. Global Urokinase Injection Revenue Market Share by Application (2021–2026)
Table 70. Global Urokinase Injection Revenue Market Share by Application (2027–2032)
Table 71. Global Urokinase Injection Price (US$/Unit) by Application (2021–2026)
Table 72. Global Urokinase Injection Price (US$/Unit) by Application (2027–2032)
Table 73. Syner-Med Company Information
Table 74. Syner-Med Description and Business Overview
Table 75. Syner-Med Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 76. Syner-Med Urokinase Injection Product
Table 77. Syner-Med Recent Developments/Updates
Table 78. Wanhua Biochem Company Information
Table 79. Wanhua Biochem Description and Business Overview
Table 80. Wanhua Biochem Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 81. Wanhua Biochem Urokinase Injection Product
Table 82. Wanhua Biochem Recent Developments/Updates
Table 83. Jiangxi Haoran Bio-Pharma Company Information
Table 84. Jiangxi Haoran Bio-Pharma Description and Business Overview
Table 85. Jiangxi Haoran Bio-Pharma Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 86. Jiangxi Haoran Bio-Pharma Urokinase Injection Product
Table 87. Jiangxi Haoran Bio-Pharma Recent Developments/Updates
Table 88. Jiangsu Aidea Pharmaceutical Company Information
Table 89. Jiangsu Aidea Pharmaceutical Description and Business Overview
Table 90. Jiangsu Aidea Pharmaceutical Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 91. Jiangsu Aidea Pharmaceutical Urokinase Injection Product
Table 92. Jiangsu Aidea Pharmaceutical Recent Developments/Updates
Table 93. Techpool Company Information
Table 94. Techpool Description and Business Overview
Table 95. Techpool Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 96. Techpool Urokinase Injection Product
Table 97. Techpool Recent Developments/Updates
Table 98. Microbic Biosystems Company Information
Table 99. Microbic Biosystems Description and Business Overview
Table 100. Microbic Biosystems Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 101. Microbic Biosystems Urokinase Injection Product
Table 102. Microbic Biosystems Recent Developments/Updates
Table 103. LIVZON Company Information
Table 104. LIVZON Description and Business Overview
Table 105. LIVZON Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 106. LIVZON Urokinase Injection Product
Table 107. LIVZON Recent Developments/Updates
Table 108. Wuhan Humanwell Pharma Company Information
Table 109. Wuhan Humanwell Pharma Description and Business Overview
Table 110. Wuhan Humanwell Pharma Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 111. Wuhan Humanwell Pharma Urokinase Injection Product
Table 112. Wuhan Humanwell Pharma Recent Developments/Updates
Table 113. Tianjin Biochem Pharma Company Information
Table 114. Tianjin Biochem Pharma Description and Business Overview
Table 115. Tianjin Biochem Pharma Urokinase Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 116. Tianjin Biochem Pharma Urokinase Injection Product
Table 117. Tianjin Biochem Pharma Recent Developments/Updates
Table 118. Key Raw Materials Lists
Table 119. Raw Materials Key Suppliers Lists
Table 120. Urokinase Injection Distributors List
Table 121. Urokinase Injection Customers List
Table 122. Urokinase Injection Market Trends
Table 123. Urokinase Injection Market Drivers
Table 124. Urokinase Injection Market Challenges
Table 125. Urokinase Injection Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
Table 129. Authors List of This Report
List of Figures
Figure 1. Product Picture of Urokinase Injection
Figure 2. Global Urokinase Injection Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Urokinase Injection Market Share by Type: 2025 & 2032
Figure 4. 10000-100000IU Product Picture
Figure 5. 100000-1000000IU Product Picture
Figure 6. Others Product Picture
Figure 7. Global Urokinase Injection Market Value by Clinical Use (US$ Million), 2021–2032
Figure 8. Global Urokinase Injection Market Share by Clinical Use: 2025 vs 2032
Figure 9. Pulmonary Embolism Thrombolysis Product Picture
Figure 10. Deep Vein Thrombosis Product Picture
Figure 11. Peripheral Arterial Occlusion Thrombolysis Product Picture
Figure 12. Catheter / Cannula Occlusion Clearance Product Picture
Figure 13. Others Product Picture
Figure 14. Global Urokinase Injection Market Value by Administration Approach (US$ Million), 2021–2032
Figure 15. Global Urokinase Injection Market Share by Administration Approach: 2025 vs 2032
Figure 16. Systemic Infusion Product Picture
Figure 17. Catheter-directed Thrombolysis (CDT) Product Picture
Figure 18. Intracatheter Dwell / Lock Technique Product Picture
Figure 19. Global Urokinase Injection Market Value by Purity (US$ Million), 2021–2032
Figure 20. Global Urokinase Injection Market Share by Purity: 2025 vs 2032
Figure 21. Standard Clinical Grade Product Picture
Figure 22. High-purity / Low-impurity Grade Product Picture
Figure 23. Low Endotoxin / Low Bioburden Specifications Product Picture
Figure 24. Global Urokinase Injection Market Value by Application (US$ Million), 2021–2032
Figure 25. Global Urokinase Injection Market Share by Application: 2025 & 2032
Figure 26. Hospital
Figure 27. Clinic
Figure 28. Others
Figure 29. Global Urokinase Injection Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 30. Global Urokinase Injection Market Size (US$ Million), 2021–2032
Figure 31. Global Urokinase Injection Sales (K Units), 2021–2032
Figure 32. Global Urokinase Injection Average Price (US$/Unit), 2021–2032
Figure 33. Urokinase Injection Report Years Considered
Figure 34. Urokinase Injection Sales Share by Manufacturers in 2025
Figure 35. Global Urokinase Injection Revenue Share by Manufacturers in 2025
Figure 36. Top 5 and Top 10 Global Urokinase Injection Players: Market Share by Revenue in Urokinase Injection in 2025
Figure 37. Urokinase Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 38. Global Urokinase Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 39. North America Urokinase Injection Sales Market Share by Country (2021–2032)
Figure 40. North America Urokinase Injection Revenue Market Share by Country (2021–2032)
Figure 41. United States Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Canada Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Europe Urokinase Injection Sales Market Share by Country (2021–2032)
Figure 44. Europe Urokinase Injection Revenue Market Share by Country (2021–2032)
Figure 45. Germany Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. France Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. U.K. Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Italy Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Russia Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Asia Pacific Urokinase Injection Sales Market Share by Region (2021–2032)
Figure 51. Asia Pacific Urokinase Injection Revenue Market Share by Region (2021–2032)
Figure 52. China Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Japan Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. South Korea Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. India Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Australia Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. China Taiwan Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Indonesia Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Thailand Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Malaysia Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Latin America Urokinase Injection Sales Market Share by Country (2021–2032)
Figure 62. Latin America Urokinase Injection Revenue Market Share by Country (2021–2032)
Figure 63. Mexico Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 64. Brazil Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Argentina Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 66. Middle East and Africa Urokinase Injection Sales Market Share by Country (2021–2032)
Figure 67. Middle East and Africa Urokinase Injection Revenue Market Share by Country (2021–2032)
Figure 68. Turkey Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 69. Saudi Arabia Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 70. UAE Urokinase Injection Revenue Growth Rate (US$ Million), 2021–2032
Figure 71. Global Sales Market Share of Urokinase Injection by Type (2021–2032)
Figure 72. Global Revenue Market Share of Urokinase Injection by Type (2021–2032)
Figure 73. Global Urokinase Injection Price (US$/Unit) by Type (2021–2032)
Figure 74. Global Sales Market Share of Urokinase Injection by Application (2021–2032)
Figure 75. Global Revenue Market Share of Urokinase Injection by Application (2021–2032)
Figure 76. Global Urokinase Injection Price (US$/Unit) by Application (2021–2032)
Figure 77. Urokinase Injection Value Chain
Figure 78. Channels of Distribution (Direct Vs Distribution)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
